Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7

Vaccine

Volumn 30, Issue 28, 2012, Pages 4259-4266

  Henken, F E ^a   Oosterhuis, K ^b   ohlschlager P ^c   Bosch, L ^a   Hooijberg, E ^a   Haanen, J B A G ^b   Steenbergen, R D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c AACHEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

DNA vaccination; E6; E7; Gene shuffling; HPV16

Indexed keywords

ACTIN; DNA VACCINE; MESSENGER RNA; PROTEIN E6; PROTEIN E6WT; PROTEIN E7; PROTEIN E7WT; PROTEIN P53; RETINOBLASTOMA PROTEIN; TETANUS TOXIN; TTFC E6SH FUSION PROTEIN; TTFC E7SH FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL IMMORTALIZATION; CELL STRAIN 3T3; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG SAFETY; EVALUATION; FIBROBLAST; GENITAL TRACT CANCER; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; KERATINOCYTE; MALIGNANT TRANSFORMATION; MOUSE; NEWBORN; NONHUMAN; PERSISTENT VIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; RETROVIRUS; RISK REDUCTION; T LYMPHOCYTE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA SHUFFLING; GENE EXPRESSION; HUMANS; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; TETANUS TOXOID; TRANSDUCTION, GENETIC; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84861679551     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.013     Document Type: Article

References (48)

1. Scheurer M.E., Tortolero-Luna G., Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. International Journal of Gynecology and Cancer 2005, 15(September (5)):727-746.
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002, 55(April (4)):244-265.
3. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002, 2(May (5)):342-350.
4. Snijders P.J., Steenbergen R.D., Heideman D.A., Meijer C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. Journal of Pathology 2006, 208(January (2)):152-164.
5. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nature Reviews Cancer 2011, 11(January (1)):9-22.
6. Knebel Doeberitz M., Rittmuller C., Aengeneyndt F., Jansen-Durr P., Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. Journal of Virology 1994, 68(May (5)):2811-2821.
7. Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Molecular and Cellular Biology 1993, 13(August (8)):4918-4927.
8. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384(February (2)):324-334.
9. Dyson N., Guida P., Munger K., Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. Journal of Virology 1992, 66(December (12)):6893-6902.
10. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384(February (2)):335-344.
11. Davies R., Hicks R., Crook T., Morris J., Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. Journal of Virology 1993, 67(May (5)):2521-2528.
12. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology 2004, 4(January (1)):46-54.
13. Brinkman J.A., Hughes S.H., Stone P., Caffrey A.S., Muderspach L.I., Roman L.D., et al. Therapeutic vaccination for HPV induced cervical cancers. Disease Markers 2007, 23(4):337-352.
14. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgonne H., Kimman T.G. Preclinical and clinical safety studies on DNA vaccines. Human Vaccine 2006, 2(March (2)):45-53.
15. Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Annals of the New York Academy of Sciences 1995, 772(November):30-39.
16. Cassetti M.C., McElhiney S.P., Shahabi V., Pullen J.K., Le Poole I.C., Eiben G.L., et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22(January (3-4)):520-527.
17. Smahel M., Sima P., Ludvikova V., Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001, 281(March (2)):231-238.
18. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347(June (9014)):1523-1527.
19. Polakova I., Pokorna D., Duskova M., Smahel M. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Vaccine 2010, 28(February (6)):1506-1513.
20. Wu T.C. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. European Journal of Immunology 2007, 37(February (2)):310-314.
21. Ohlschlager P., Pes M., Osen W., Durst M., Schneider A., Gissmann L., et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006, 24(April (15)):2880-2893.
22. Oosterhuis K., Ohlschlager P., van den Berg J.H., Toebes M., Gomez R., Schumacher T.N., et al. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. International Journal of Cancer 2011, (January).
23. Osen W., Peiler T., Ohlschlager P., Caldeira S., Faath S., Michel N., et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001, 19(July (30)):4276-4286.
24. Bins A.D., Jorritsma A., Wolkers M.C., Hung C.F., Wu T.C., Schumacher T.N., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature Medicine 2005, 11(August (8)):899-904.
25. van den Berg J.H., Nuijen B., Beijnen J.H., Vincent A., van Tinteren H., Kluge J., et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Human Gene Therapy 2008, (November).
26. Durst M., Dzarlieva-Petrusevska R.T., Boukamp P., Fusenig N.E., Gissmann L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1987, 1(3):251-256.
27. Massimi P., Banks L. Transformation assays for HPV oncoproteins. Methods in Molecular Medicine 2005, 119:381-395.
28. Steenbergen R.D., Walboomers J.M., Meijer C.J., van der Raaij-Helmer E.M., Parker J.N., Chow L.T., et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996, 13(September (6)):1249-1257.
29. Kinsella T.M., Nolan G.P. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Human Gene Therapy 1996, 7(August (12)):1405-1413.
30. Heemskerk M.H., Blom B., Nolan G., Stegmann A.P., Bakker A.Q., Weijer K., et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. Journal of Experimental Medicine 1997, 186(November (9)):1597-1602.
31. Hanke T., Schneider J., Gilbert S.C., Hill A.V., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998, 16(February (4)):426-435.
32. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(September (20)):9363-9367.
33. Henken F.E., Banerjee N.S., Snijders P.J., Meijer C.J., Castro Arce J., Rosl F., et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Molecular Cancer 2011, 10:71.
34. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology 1989, 63(October (10)):4417-4421.
35. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63(December (6)):1129-1136.
36. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Research 1996, 56(October (20)):4620-4624.
37. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380(March (6569)):79-82.
38. Liu X., Roberts J., Dakic A., Zhang Y., Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 2008, 375(June (2)):611-623.
39. Yasumoto S., Burkhardt A.L., Doniger J., DiPaolo J.A. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. Journal of Virology 1986, 57(February (2)):572-577.
40. Schlegel R., Phelps W.C., Zhang Y.L., Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO Journal 1988, 7(October (10)):3181-3187.
41. Woodworth C.D., Doniger J., DiPaolo J.A. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. Journal of Virology 1989, 63(January (1)):159-164.
42. Sedman S.A., Barbosa M.S., Vass W.C., Hubbert N.L., Haas J.A., Lowy D.R., et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. Journal of Virology 1991, 65(September (9)):4860-4866.
43. Vousden K.H., Doniger J., DiPaolo J.A., Lowy D.R. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Research 1988, 3(September (2)):167-175.
44. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO Journal 1989, 8(December (12)):3905-3910.
45. Hudson J.B., Bedell M.A., McCance D.J., Laiminis L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. Journal of Virology 1990, 64(February (2)):519-526.
46. Kaur P., McDougall J.K. Characterization of primary human keratinocytes transformed by human papillomavirus type 18. Journal of Virology 1988, 62(June (6)):1917-1924.
47. Hahn W.C. Immortalization and transformation of human cells. Molecules and Cells 2002, 13(June (3)):351-361.
48. Halbert C.L., Demers G.W., Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. Journal of Virology 1991, 65(January (1)):473-478.